샘플 요청 목록

 카트 문의
시장보고서
상품코드
1586430

GLP-1 유사체 시장 규모, 점유율, 동향, 산업 분석 보고서 : 투여 경로별, 제품별, 용도별, 유통 채널별, 지역별 - 시장 예측(2025-2034년)

GLP-1 Analogues Market Size, Share, Trends, Industry Analysis Report: By Route of Administration, Product, Application, Distribution Channel, and Region - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 GLP-1 유사체 시장 규모는 2034년까지 3,228억 5,000만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

GLP-1 유사체 시장은 제2형 당뇨병과 비만 유병률 증가, 의료 인프라의 급속한 발전, 만성질환에 대한 인식의 증가 등을 배경으로 큰 성장세를 보이고 있습니다. 글루카곤 유사 펩타이드-1(GLP-1) 유사체는 혈당 및 식욕 조절에 중요한 역할을 하는 천연 유래 호르몬 GLP-1의 작용을 모방한 의약품의 일종입니다. 이러한 유사체들은 제2형 당뇨병 관리에 필수적인 역할을 하고 있습니다. 최근에는 비만 치료제로도 승인되어 시장 성장이 더욱 확대되고 있습니다.

GLP-1 유사체 시장의 성장 촉진요인은 제2형 당뇨병의 유병률 증가입니다. 이러한 유병률 증가는 가공식품, 설탕, 지방이 많은 건강에 해로운 식습관, 앉아서 생활하는 습관 등 라이프스타일의 변화에 기인합니다. 도시화가 진행되면서 당뇨병 발병의 위험 요인으로 알려진 서유럽화된 식습관과 생활방식을 받아들이는 사람들이 많아졌습니다. 또한, 고령화도 제2형 당뇨병 발병률 상승의 한 요인으로 작용하고 있습니다. 이러한 요인들로 인해 효과적인 당뇨병 치료제에 대한 수요가 급증하고 있으며, 특히 GLP-1 유사체는 혈당을 낮추고 심혈관계 질환의 위험을 감소시키는 효과가 입증된 GLP-1 유사체가 가장 많이 사용되고 있습니다.

비만의 증가도 GLP-1 유사체 시장 성장의 중요한 촉진요인입니다. 비만 유병률은 전 세계적으로 증가하고 있으며, 특히 아시아태평양과 같이 급속한 경제 성장과 도시화가 진행되고 있는 지역에서 두드러지게 나타나고 있습니다. 이 지역에서는 중산층 인구가 증가함에 따라 칼로리가 높고 영양가가 낮은 식품의 소비가 증가하고 운동량이 감소하여 비만율 증가에 기여하고 있습니다. 체중 조절을 위한 GLP-1 유사체의 승인은 시장 성장의 새로운 기회를 제공하고 있습니다. 또한, 특히 신흥국의 의료 인프라가 발전함에 따라 이러한 치료법이 더 쉽게 접근할 수 있게 되었습니다. 정부와 민간 의료 서비스 제공자들은 진단 능력 향상과 의료 서비스 확대에 투자하여 당뇨병과 비만을 조기에 발견하고 보다 효과적으로 관리할 수 있도록 하고 있습니다. 또한, 원격의료와 온라인 약국 도입이 확대되면서 GLP-1 유사체에 대한 접근성이 향상되고 있으며, 특히 원격지나 의료 서비스가 부족한 지역에서 GLP-1 유사체 접근성이 향상되고 있어 시장 성장을 더욱 촉진하고 있습니다.

GLP-1 유사체 시장 보고서 하이라이트

제품 유형별로는 제2형 당뇨병 환자의 혈당 조절에 효과가 높은 오젬픽이 2024년 GLP-1 유사체 시장에서 가장 큰 매출 점유율을 차지했습니다.

판매 채널별 온라인 약국 부문은 인터넷 보급 확대와 경쟁적인 가격 전략으로 인해 예측 기간 동안 상당한 CAGR을 기록할 것으로 예상됩니다.

2024년 북미는 높은 제2형 당뇨병과 비만 유병률로 인해 가장 큰 시장 점유율을 차지했습니다.

아시아태평양 시장은 헬스케어에 대한 접근성 확대와 중산층 인구 증가로 인해 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다.

세계 주요 시장 진입 기업으로는 AstraZeneca; Bristol-Myers Squibb Company; D&D Pharmatech; Eccogen; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Hanmi Pharm. Co., Ltd.; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk A/S; Sanofi. 등이 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 조사 방법

제4장 세계의 GLP-1 유사체 시장 인사이트

  • 애플리케이션 현황
  • GLP-1 유사체 시장 역학
    • 성장 촉진요인과 기회
      • 고령화 인구 증가가 시장 성장을 견인
      • 2형 당뇨병 이환율 증가가 시장 성장을 견인
    • 성장 억제요인과 과제
      • 대체 의약품과의 경쟁이 GLP-1 유사체 시장 성장을 방해하고 있다
  • PESTEL 분석
  • GLP-1 유사체 시장 애플리케이션 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 GLP-1 유사체 시장 : 투여 경로별

  • 주요 조사 결과
  • 소개
  • 비경구 투여
  • 경구 투여

제6장 세계의 GLP-1 유사체 시장 : 제품별

  • 주요 조사 결과
  • 소개
  • Ozempic
  • Trulicity
  • Mounjaro
  • Wegovy
  • Rybelsus
  • Saxenda
  • Victoza
  • Zepbound
  • 기타 제품

제7장 세계의 GLP-1 유사체 시장 : 용도별

  • 주요 조사 결과
  • 소개
  • 2형 당뇨병
  • 비만

제8장 세계의 GLP-1 유사체 시장 : 유통 채널별

  • 주요 조사 결과
  • 소개
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제9장 세계의 GLP-1 유사체 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • GLP-1 유사체 시장 평가 : 지역별, 2020-2034년
  • 북미
    • 북미 : 투여 경로별, 2020-2034년
    • 북미 : 제품별, 2020-2034년
    • 북미 : 용도별, 2020-2034년
    • 북미 : 유통 채널별, 2020-2034년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 투여 경로별, 2020-2034년
    • 유럽 : 제품별, 2020-2034년
    • 유럽 : 용도별, 2020-2034년
    • 유럽 : 유통 채널별, 2020-2034년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 투여 경로별, 2020-2034년
    • 아시아태평양 : 제품별, 2020-2034년
    • 아시아태평양 : 용도별, 2020-2034년
    • 아시아태평양 : 유통 채널별, 2020-2034년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 투여 경로별, 2020-2034년
    • 중동 및 아프리카 : 제품별, 2020-2034년
    • 중동 및 아프리카 : 용도별, 2020-2034년
    • 중동 및 아프리카 : 유통 채널별, 2020-2034년
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 투여 경로별, 2020-2034년
    • 라틴아메리카 : 제품별, 2020-2034년
    • 라틴아메리카 : 용도별, 2020-2034년
    • 라틴아메리카 : 유통 채널별, 2020-2034년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제10장 경쟁 상황

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제11장 기업 개요

  • AstraZeneca.
  • Bristol-Myers Squibb Company
  • D&D Pharmatech
  • Eccogen
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Hanmi Pharm. Co., Ltd.
  • Lexicon Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Sanofi
  • Rollins, Inc
  • Sumitomo Chemical Company, Limited
  • Syngenta
  • Terminix
ksm 24.11.26

The global GLP-1 analogues market size is expected to reach USD 322.85 billion by 2034, according to a new study by Polaris Market Research. The report "GLP-1 Analogues Market Share, Size, Trends, Industry Analysis Report - By Route of Administration (Subcutaneous Route and Oral Route), Product, Application, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Segment Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The GLP-1 analogues market has been witnessing significant growth, driven by the increasing prevalence of type 2 diabetes and obesity, surging advancements in healthcare infrastructure, and rising awareness of these chronic conditions. Glucagon-like peptide-1 (GLP-1) analogues are a class of medications that mimic the action of the naturally occurring hormone GLP-1, which plays a crucial role in regulating blood sugar levels and appetite. These analogues have become essential in managing type 2 diabetes. Recently, they have gained approval for obesity treatment, further expanding their market growth.

The primary growth driver for the GLP-1 analogues market is the escalating prevalence of type 2 diabetes. This increase in disease prevalence is largely attributed to lifestyle changes, such as unhealthy diets rich in processed foods, sugar, and fats, combined with sedentary behaviors. The rise in urbanization has led to more people adopting a Westernized diet and lifestyle, which are known risk factors for developing diabetes. Additionally, the aging population is contributing to the higher incidence of type 2 diabetes, as the risk of developing the condition increases with age. These factors have led to a surge in demand for effective diabetes treatments, with GLP-1 analogues being at the forefront due to their proven efficacy in lowering blood glucose levels and reducing the risk of cardiovascular events.

The rising prevalence of obesity is another significant driver of the GLP-1 analogues market growth. Obesity prevalence is increasing globally, particularly in regions undergoing rapid economic growth and urbanization, such as Asia Pacific. The growing middle-class population in these regions is leading to increased consumption of calorie-dense, low-nutrient foods and reduced physical activity, both of which contribute to rising obesity rates. The approval of GLP-1 analogues for weight management has opened up new opportunities for market growth. Furthermore, advancements in healthcare infrastructure, particularly in emerging economies, are making these treatments more accessible. Governments and private healthcare providers are investing in improving diagnostic capabilities and expanding healthcare services, enabling earlier detection and more effective management of diabetes and obesity. Additionally, the growing adoption of telemedicine and online pharmacies is enhancing access to GLP-1 analogues, especially in remote and underserved areas, further driving the market growth.

GLP-1 Analogues Market Report Highlights

By product, in 2024, the ozempic segment accounted for the largest revenue share in the GLP-1 analogues market due to its strong efficacy in managing blood glucose levels in individuals affected by type 2 diabetes.

The online pharmacies segment, based on distribution channel, is expected to record a significant CAGR during the forecast period due to expanding internet penetration and competitive pricing strategies.

In 2024, North America accounted for the largest market share due to the high prevalence of type 2 diabetes and obesity.

The Asia Pacific market is expected to record the highest CAGR during the forecast period due to the expanding healthcare access and growing middle-class population.

A few global key market players are AstraZeneca; Bristol-Myers Squibb Company; D&D Pharmatech; Eccogen; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Hanmi Pharm. Co., Ltd.; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk A/S; and Sanofi.

Polaris Market Research has segmented the GLP-1 analogues market report on the basis of route of administration, product, application, distribution channel, and region:

By Route of Administration Outlook (Revenue - USD Billion, 2020-2034)

  • Subcutaneous Route
  • Oral Route

By Product Outlook (Revenue - USD Billion, 2020-2034)

  • Ozempic
  • Trulicity
  • Mounjaro
  • Wegovy
  • Rybelsus
  • Saxenda
  • Victoza
  • Zepbound
  • Other Products

By Application Outlook (Revenue - USD Billion, 2020-2034)

  • Type 2 Diabetes Mellitus
  • Obesity
  • Others Applications

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global GLP-1 Analogues Market Insights

  • 4.1. GLP-1 Analogues Market - Application Snapshot
  • 4.2. GLP-1 Analogues Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The Rise of the Aging Population is Driving Market Growth
      • 4.2.1.2. The Increasing Prevalence of Type 2 Diabetes Are Driving the Market Growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Competition from Alternative Drugs are hindering the GLP-1 Analogues market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. GLP-1 Analogues Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global GLP-1 Analogues Market, by Route of Administration

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
  • 5.3. Parenteral Route
    • 5.3.1. Global GLP-1 Analogues Market, by Parenteral Route, by Region, 2020-2034 (USD Billion)
  • 5.4. Oral Route
    • 5.4.1. Global GLP-1 Analogues Market, by Oral Route, by Region, 2020-2034 (USD Billion)

6. Global GLP-1 Analogues Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
  • 6.3. Ozempic
    • 6.3.1. Global GLP-1 Analogues Market, by Ozempic, by Region, 2020-2034 (USD Billion)
  • 6.4. Trulicity
    • 6.4.1. Global GLP-1 Analogues Market, by Trulicity, by Region, 2020-2034 (USD Billion)
  • 6.5. Mounjaro
    • 6.5.1. Global GLP-1 Analogues Market, by Mounjaro, by Region, 2020-2034 (USD Billion)
  • 6.6. Wegovy
    • 6.6.1. Global GLP-1 Analogues Market, by Wegovy, by Region, 2020-2034 (USD Billion)
  • 6.7. Rybelsus
    • 6.7.1. Global GLP-1 Analogues Market, by Rybelsus, by Region, 2020-2034 (USD Billion)
  • 6.8. Saxenda
    • 6.8.1. Global GLP-1 Analogues Market, by Saxenda, by Region, 2020-2034 (USD Billion)
  • 6.9. Victoza
    • 6.9.1. Global GLP-1 Analogues Market, by Victoza, by Region, 2020-2034 (USD Billion)
  • 6.10. Zepbound
    • 6.10.1. Global GLP-1 Analogues Market, by Zepbound, by Region, 2020-2034 (USD Billion)
  • 6.11. Other Products
    • 6.11.1. Global GLP-1 Analogues Market, by Other Products, by Region, 2020-2034 (USD Billion)

7. Global GLP-1 Analogues Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
  • 7.3. Type 2 Diabetes Mellitus
    • 7.3.1. Global GLP-1 Analogues Market, by Type 2 Diabetes Mellitus, by Region, 2020-2034 (USD Billion)
  • 7.4. Obesity
    • 7.4.1. Global GLP-1 Analogues Market, by Obesity, by Region, 2020-2034 (USD Billion)

8. Global GLP-1 Analogues Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.3. Hospital Pharmacies
    • 8.3.1. Global GLP-1 Analogues Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 8.4. Retail Pharmacies
    • 8.4.1. Global GLP-1 Analogues Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)
  • 8.5. Online Pharmacies
    • 8.5.1. Global GLP-1 Analogues Market, by Online Pharmacies, by Region, 2020-2034 (USD Billion)

9. Global GLP-1 Analogues Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. GLP-1 Analogues Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 9.3. GLP-1 Analogues Market - North America
    • 9.3.1. North America: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.3.2. North America: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
    • 9.3.3. North America: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
    • 9.3.4. North America: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.3.5. GLP-1 Analogues Market - U.S.
      • 9.3.5.1. U.S.: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.3.5.2. U.S.: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.3.5.3. U.S.: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.3.5.4. U.S.: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.3.6. GLP-1 Analogues Market - Canada
      • 9.3.6.1. Canada: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.3.6.2. Canada: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.3.6.3. Canada: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.3.6.4. Canada: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 9.4. GLP-1 Analogues Market - Europe
    • 9.4.1. Europe: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.2. Europe: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
    • 9.4.3. Europe: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
    • 9.4.4. Europe: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.5. GLP-1 Analogues Market - UK
      • 9.4.5.1. UK: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.5.2. UK: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.4.5.3. UK: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.4.5.4. UK: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.6. GLP-1 Analogues Market - France
      • 9.4.6.1. France: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.6.2. France: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.4.6.3. France: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.4.6.4. France: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.7. GLP-1 Analogues Market - Germany
      • 9.4.7.1. Germany: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.7.2. Germany: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.4.7.3. Germany: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.4.7.4. Germany: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.8. GLP-1 Analogues Market - Italy
      • 9.4.8.1. Italy: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.8.2. Italy: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.4.8.3. Italy: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.4.8.4. Italy: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.9. GLP-1 Analogues Market - Spain
      • 9.4.9.1. Spain: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.9.2. Spain: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.4.9.3. Spain: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.4.9.4. Spain: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.10. GLP-1 Analogues Market - Netherlands
      • 9.4.10.1. Netherlands: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.10.2. Netherlands: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.4.10.3. Netherlands: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.4.10.4. Netherlands: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.11. GLP-1 Analogues Market - Russia
      • 9.4.11.1. Russia: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.11.2. Russia: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.4.11.3. Russia: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.4.11.4. Russia: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.12. GLP-1 Analogues Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.12.2. Rest of Europe: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.4.12.3. Rest of Europe: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.4.12.4. Rest of Europe: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 9.5. GLP-1 Analogues Market - Asia Pacific
    • 9.5.1. Asia Pacific: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.2. Asia Pacific: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
    • 9.5.3. Asia Pacific: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
    • 9.5.4. Asia Pacific: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.5. GLP-1 Analogues Market - China
      • 9.5.5.1. China: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.5.2. China: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.5.5.3. China: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.5.5.4. China: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.6. GLP-1 Analogues Market - India
      • 9.5.6.1. India: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.6.2. India: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.5.6.3. India: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.5.6.4. India: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.7. GLP-1 Analogues Market - Malaysia
      • 9.5.7.1. Malaysia: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.7.2. Malaysia: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.5.7.3. Malaysia: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.5.7.4. Malaysia: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.8. GLP-1 Analogues Market - Japan
      • 9.5.8.1. Japan: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.8.2. Japan: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.5.8.3. Japan: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.5.8.4. Japan: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.9. GLP-1 Analogues Market - Indonesia
      • 9.5.9.1. Indonesia: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.9.2. Indonesia: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.5.9.3. Indonesia: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.5.9.4. Indonesia: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.10. GLP-1 Analogues Market - South Korea
      • 9.5.10.1. South Korea: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.10.2. South Korea: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.5.10.3. South Korea: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.5.10.4. South Korea: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.11. GLP-1 Analogues Market - Australia
      • 9.5.11.1. Australia: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.11.2. Australia: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.5.11.3. Australia: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.5.11.4. Australia: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.12. GLP-1 Analogues Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.12.2. Rest of Asia Pacific: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.5.12.3. Rest of Asia Pacific: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.5.12.4. Rest of Asia Pacific: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 9.6. GLP-1 Analogues Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.6.2. Middle East & Africa: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
    • 9.6.3. Middle East & Africa: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
    • 9.6.4. Middle East & Africa: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.6.5. GLP-1 Analogues Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.5.2. Saudi Arabia: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.6.5.3. Saudi Arabia: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.6.5.4. Saudi Arabia: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.6.6. GLP-1 Analogues Market - UAE
      • 9.6.6.1. UAE: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.6.2. UAE: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.6.6.3. UAE: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.6.6.4. UAE: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.6.7. GLP-1 Analogues Market - Israel
      • 9.6.7.1. Israel: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.7.2. Israel: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.6.7.3. Israel: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.6.7.4. Israel: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.6.8. GLP-1 Analogues Market - South Africa
      • 9.6.8.1. South Africa: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.8.2. South Africa: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.6.8.3. South Africa: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.6.8.4. South Africa: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.6.9. GLP-1 Analogues Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.9.2. Rest of Middle East & Africa: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.6.9.3. Rest of Middle East & Africa: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.6.9.4. Rest of Middle East & Africa: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 9.7. GLP-1 Analogues Market - Latin America
    • 9.7.1. Latin America: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.7.2. Latin America: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
    • 9.7.3. Latin America: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
    • 9.7.4. Latin America: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.7.5. GLP-1 Analogues Market - Mexico
      • 9.7.5.1. Mexico: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.7.5.2. Mexico: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.7.5.3. Mexico: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.7.5.4. Mexico: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.7.6. GLP-1 Analogues Market - Brazil
      • 9.7.6.1. Brazil: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.7.6.2. Brazil: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.7.6.3. Brazil: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.7.6.4. Brazil: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.7.7. GLP-1 Analogues Market - Argentina
      • 9.7.7.1. Argentina: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.7.7.2. Argentina: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.7.7.3. Argentina: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.7.7.4. Argentina: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.7.8. GLP-1 Analogues Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: GLP-1 Analogues Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.7.8.2. Rest of Latin America: GLP-1 Analogues Market, by Product, 2020-2034 (USD Billion)
      • 9.7.8.3. Rest of Latin America: GLP-1 Analogues Market, by Application, 2020-2034 (USD Billion)
      • 9.7.8.4. Rest of Latin America: GLP-1 Analogues Market, by Distribution Channel, 2020-2034 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. AstraZeneca.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Bristol-Myers Squibb Company
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. D&D Pharmatech
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Eccogen
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Eli Lilly and Company
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Glenmark Pharmaceuticals Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Hanmi Pharm. Co., Ltd.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Lexicon Pharmaceuticals, Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Merck & Co., Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Novo Nordisk A/S
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Sanofi
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Rollins, Inc
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Sumitomo Chemical Company, Limited
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Syngenta
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Terminix
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제